Welcome to our dedicated page for Aprea Therapeutics SEC filings (Ticker: APRE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Aprea Therapeutics, Inc. filings document the regulatory record of a Nasdaq-listed clinical-stage oncology company developing targeted therapies for biomarker-defined cancers. Its Form 8-K disclosures cover material events such as clinical updates for APR-1051, operating and financial results, corporate presentation updates, private-placement financing, capital-structure information, and Nasdaq listing-compliance notices.
Proxy materials for Aprea address annual meeting procedures and shareholder voting matters. The filing record also identifies the company’s common stock under the symbol APRE and provides formal disclosures tied to governance, financing activity, public-company reporting obligations, and the development status of its precision medicine oncology programs.
Aprea Therapeutics, Inc. (APRE) reported an expansion of its global intellectual property portfolio supporting its precision oncology programs. The company now has 28 issued and 30 pending patents across its pipeline. The WEE1 kinase inhibitor program, including lead asset APR-1051, is covered by two pending U.S. patent applications, one pending U.S. provisional, two granted non-U.S. patents in Australia and Korea, and 12 pending non-U.S. applications. This WEE1 family, if granted, would expire in 2047 and covers proprietary compounds, compositions, and methods of use.
The ATR inhibitor program, including ATRN-119, is protected by four granted U.S. patents, one pending U.S. application, one pending international application, 22 granted non-U.S. patents, and 13 pending non-U.S. applications, with granted patents expiring between 2035–2037 and potential extension to 2045 plus up to five years of regulatory exclusivities. Aprea previously set an RP2D of 1,100 mg once daily for ATRN-119 but closed that study to prioritize APR-1051, while considering ATRN-119 for future combination strategies.
Aprea Therapeutics, Inc. has an updated Schedule 13G/A reporting the holdings of Laurence W. Lytton. Lytton is disclosed as beneficially owning 390,807 shares of Aprea common stock, representing 3.2% of the class. This percentage is calculated using 12,382,776 shares outstanding as of May 13, 2026, as reported by the company for the quarter ended March 31, 2026.
Within this position, Lytton holds 322,220 shares with sole voting and dispositive power and 68,587 shares with shared voting and dispositive power. The filing reflects Amendment No. 1 and confirms his U.S. citizenship and contact details as the reporting person.
Aprea Therapeutics, Inc. is a clinical-stage oncology company developing targeted, synthetic lethality-based therapies. For the quarter ended June 30, 2026, it reported a net loss of $3.6 million (basic and diluted $0.07 per share) with no grant revenue, compared with a $3.2 million loss a year earlier. Research and development expenses rose to $2.5 million, driven mainly by its lead WEE1 inhibitor APR-1051, while general and administrative costs were steady at about $1.6 million.
Cash, cash equivalents and restricted cash increased sharply to $41.3 million at June 30, 2026 from $14.6 million at year-end 2025, primarily due to three late-2025 and early-2026 private placements and warrant financings totaling roughly $38.7 million in upfront gross proceeds. The company states this cash should fund operations into the first quarter of 2028.
Clinically, APR-1051 showed early activity in the Phase 1 ACESOT-1051 study, including two partial responses in PPP2R1A-mutated endometrial cancer and multiple patients with stable disease. Enrollment is expanding, with a larger cohort planned in uterine serous carcinoma and cyclin E-overexpressing platinum-resistant ovarian cancer. ATR inhibitor ATRN-119 completed dose escalation in the ABOYA-119 study; development is now focused on potential combination regimens. A macrocyclic DYRK1A/B inhibitor remains in preclinical development with possible IND-enabling entry in late 2026, subject to resources.
Aprea Therapeutics, Inc. reported second quarter ended June 30, 2026 results and provided a business update centered on its lead oral WEE1 inhibitor APR-1051. Enrollment in the Phase 1 dose escalation ACESOT-1051 trial is accelerating, with plans to advance APR-1051 as a single agent in uterine serous carcinoma and Cyclin E–overexpressing platinum-resistant ovarian cancer, and in combination regimens in HPV-positive head and neck cancer and colorectal cancer. Updated Phase 1 data presented at ASCO 2026 showed early single-agent activity, including partial responses and disease stabilization, with a manageable tolerability profile. The pipeline also includes ATR inhibitor ATRN-119 in clinical development for solid tumors.
Cash and cash equivalents were $41.2 million as of June 30, 2026, with total assets of $42.3 million and stockholders’ equity of $38.5 million. For the quarter, Aprea reported a net loss of $3.6 million on operating expenses of $4.0 million, primarily research and development of $2.5 million and general and administrative of $1.6 million. Six-month net loss was $6.9 million. Weighted-average basic and diluted common shares outstanding for the quarter were 53.5 million.
Aprea Therapeutics, Inc. received a notification from Nasdaq on July 23, 2026 that it qualifies for an additional 180-day Second Compliance Period, through January 19, 2027, to regain compliance with the Nasdaq Capital Market Minimum Bid Price Requirement of at least $1.00 per share under Listing Rule 5550(a)(2).
The company had previously been given until July 22, 2026 to restore compliance after its common stock fell below the $1.00 minimum bid price. If at any time during the Second Compliance Period the closing bid price of the common stock is at least $1.00 per share for a minimum of 10 consecutive business days, Nasdaq will confirm compliance. If compliance is not demonstrated by January 19, 2027, Nasdaq states it will issue a notice of delisting, which Aprea could then appeal to a hearings panel.
Aprea Therapeutics, Inc. director Michael Grissinger received equity compensation in the form of restricted stock units and stock options. On June 16, 2026, he was granted 3,135 restricted stock units that will vest and be settled in common stock on June 16, 2027, if he continues serving on the board through that date.
He also received stock options for 12,555 shares of common stock at an exercise price of $0.7293 per share, vesting in full on June 16, 2027 and expiring on June 16, 2036, subject to the same service-based condition. After these grants, he directly holds 6,024 shares of common stock and 12,555 stock options.
Aprea Therapeutics, Inc. director Gabriela Gruia received new equity compensation on June 16, 2026. She was granted 3,135 restricted stock units that will vest and settle in common stock on June 16, 2027, if she continues serving on the board through that date, with possible acceleration under certain conditions.
She also received stock options covering 12,555 shares of common stock at an exercise price of $0.7293 per share, which vest in full on June 16, 2027, subject to the same service condition and potential acceleration, and expire on June 16, 2036. Following these grants, she holds 4,180 shares of common stock directly.
Aprea Therapeutics director Richard Peters received equity-based compensation rather than trading shares on the market. On June 16, 2026, he was granted 3,135 restricted stock units that will vest and be settled in common stock on June 16, 2027, subject to his continued service on the board and potential acceleration conditions.
He also received stock options for 12,555 shares of common stock at an exercise price of $0.7293 per share, which vest in full on June 16, 2027 under the same service and acceleration conditions and expire on June 16, 2036. Following these awards, he holds 6,254 common shares directly.
Aprea Therapeutics director John B. Henneman III received new equity awards. He was granted 3,135 restricted stock units on June 16, 2026, which will vest and settle in common stock on June 16, 2027, if he remains on the board. He also received stock options for 12,555 shares of common stock at an exercise price of $0.7293 per share, vesting in full on June 16, 2027 and expiring on June 16, 2036. Following these awards, he directly holds 13,364 shares of common stock, while the options and restricted stock units represent additional potential future ownership.
Aprea Therapeutics director Jean-Pierre Bizzari received new equity awards. On June 16, 2026, he was granted 3,135 restricted stock units that will vest and settle in common stock on June 16, 2027, if he continues serving on the board and certain acceleration conditions do not apply.
He also received stock options covering 12,555 shares of common stock at an exercise price of $0.7293 per share, vesting in full on June 16, 2027 under the same service-based conditions. Following the grant, he directly holds 4,180 common shares, and the options expire on June 16, 2036.